Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. In 2003 he was one of the founders of Bioceros BV were he currently hold a position of CSO. In addition, he held position as CSO for 4AZA Bioscience NV, FF Pharma and VP Preclinical for PanGenetics BV and Tanox. Dr. Boon is author of over 280 papers in international scientific journals in the field of medical biotechnology.
Bioceros generates production cell lines and production processes for the industry and used its proprietary CHOBC® platform and its SPOT™ technology to generate a portfolio of cell lines producing biosimilar monoclonal antibodies. Since the acquisition of Bioceros by EPIRUS in 2015, he extended this expertise and developed a complete process modulation toolbox to fit biosimilar CQAs. After the acquisition of Epirus NL by the Polpharma Biologics group in June 2016, he has continued to work on biosimilar development and innovative new molecular antibody entities, which now within the Polpharma Biologics group can be progressed to GMP production and clinical testing.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October